Marc Tessier-Lavigne - Mar 16, 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**Marc Tessier-Lavigne
Stock symbol
REGN
Transactions as of
Mar 16, 2022
Transactions value $
-$3,687,055
Form type
4
Date filed
3/18/2022, 04:05 PM
Previous filing
Jan 5, 2022
Next filing
Mar 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $1.63M +4.36K +192.2% $374.12 6.63K Mar 16, 2022 Direct F1
transaction REGN Common Stock Sale -$2.94M -4.36K -65.78% $675.00 2.27K Mar 16, 2022 Direct F1
transaction REGN Common Stock Options Exercise $2.95M +7.83K +345.09% $376.69 10.1K Mar 17, 2022 Direct F1
transaction REGN Common Stock Sale -$5.32M -7.83K -77.53% $680.00 2.27K Mar 17, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -4.36K -100% $0.00* 0 Mar 16, 2022 Common Stock 4.36K $374.12 Direct F1, F2
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -7.83K -100% $0.00* 0 Mar 17, 2022 Common Stock 7.83K $376.69 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.
F3 The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.